期刊文献+

注射用海姆泊芬联合532nm KTP激光光动力治疗微静脉畸形的疗效评价 被引量:3

Clinical trial of hemporfin-532nm KTP laser photodynamic therapy for venular malformations for its efficacy
原文传递
导出
摘要 目的:在Ⅱa期临床试验基础上,探索新型光敏剂-注射用海姆泊芬联合532nm激光光动力治疗微静脉畸形的最佳剂量,初步评价该治疗方法的有效性及安全性,为后续临床试验提供依据。方法:遵循平行、对照、双盲的试验原则,对本科就诊的25例微静脉畸形患者,签署知情同意书后,按照2:2:1的比例随机分配入A组(高剂量组,5mg/kg)、B组(低剂量组,2.5mg/kg)和对照组(安慰剂组),接受不超过2个疗程的光动力治疗。光敏剂为注射用海姆泊芬冻干粉针剂,激光波长为532nm,功率密度为80~100mW/cm2,照射时间为20min。实验数据采用SAS9.1.3软件包进行统计学处理。结果:第1疗程8~12周后,A组治愈率为10.0%,总显效率为40.0%,总有效率为90.0%(n=10);B组治愈率为0.0%,总显效率为0.0%,总有效率为55.6%(n=9,脱落1例);对照组(C组)治愈率为0.0%,总显效率为0.0%,总有效率为40.0%(n=5)。A组总显效率和总有效率均优于B组,A组总有效率优于对照组(C组)(P<0.05)。第1疗程不良反应发生率分别为A组50.0%、B组22.2%和C组0.0%。第2疗程不良反应发生率为A组20%、B组33.3%和C组20%。各组间不良反应发生率无显著差异(P>0.05)。结论:注射用海姆泊芬光动力疗法用于微静脉畸形是一种安全、有效的方法。高剂量组(5mg/kg)的疗效明显优于低剂量(2.5mg/kg)组和对照组,各组间不良反应发生率无显著差异。 PURPOSE:To explore the reasonable drug dose in hemporfin photodynamic therapy(PDT) for venular malformation,and to evaluate the efficacy and safety,with the aim of providing a basis for subsequent clinical trials.METHODS:Paralleled,controlled,double-blinded.clinical trial with hemporfin used as photosensitizer,continuous laser(532nm,irradiation 80-100mW/cm2),the exposure time was 20 minutes,the subjects were 25 venular malformation patients,after signing informed consent,they were randomly assigned into 3 groups with the ratio of 2:2:1.Group A(5mg/kg,high dose),group B(2.5mg/kg,low dose) and control group(placebo),accepted not more than two session of PDT.The data was analyzed with SAS 9.1.3 software package.RESULTS:Eight to12 weeks after the first treatment,the complete response rate(CR),the partial response rate(PR),and the total efficiency rate of group A were 10.0%,40.0% and 90.0%(n=10);0.0%,0.0% and 55.6%(n=9,one drop out) for group B.The incidence of adverse effect after the first session was 50.0%(A),22.2%(B),0.0%(C),respectively.And that of the second session was 20%(A),33.3%(B),20%(C),respectively.There was no significant difference among those groups(P0.05).CONCLUSION:Hemporfin-532nm KTP laser PDT is safe and effective for venular malformation.
出处 《中国口腔颌面外科杂志》 CAS 2010年第4期294-299,共6页 China Journal of Oral and Maxillofacial Surgery
基金 上海市科学技术委员会资助项目(08DZ2271100)~~
关键词 光动力治疗 海姆泊芬 微静脉畸形 光敏剂 Photodynamic therapy Hemporfin Venular malformation Clinical trial
  • 相关文献

参考文献17

  • 1Jacobs AH,Walton RG.The incidence of birthmarks in the neonate[J]. Pediatrics, 1976 , 58(2): 218-22.
  • 2Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains [J]. J Dermatol Surg Oncol, 1991,17:76-79.
  • 3Barsky SH, Rosen S, Geer DE, et al. The nature andevolution of port-wine stains: a computer-assisted study [J].J Invest Dermatol, 1980,74:154-157.
  • 4Klapman MH,Yao JF.Thickening and nodules in port-wine stains[J]. J Am Acad Dermatol,2001,44(2):300-302.
  • 5顾瑛.光动力学疗法治疗鲜红斑痣.北京医学,1991,13(5):317-317.
  • 6顾瑛,李峻亨,江亿平,粱洁,周萍,崔效杰,潘玉明,王开.光动力学疗法选择性治疗鲜红斑痣的临床研究附40例报告[J].中国激光医学杂志,1992,1(1):6-10. 被引量:81
  • 7Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin[J]. Lasers Surg Med,1981,1:263-276.
  • 8Babilas P, Shafirstein G, Baumler W, et al. Selective photothermolysis of blood vessels following flashlamp-pumped pulsed dye laser irradiation: in vivo results and mathematical modelling are in agreement[J]. J Invest Dermatol,2005,125: 343-352.
  • 9Lanigan SW. Port-wine stains unresponsive to pulsed dye laser:Explanations and solutions[J]. Br J Dermatol,1998,139,173-177.
  • 10Lin XX, Wang W, Wu SF, et al. Treatment of capillary vascular malformation (port-wine stains) with photochemotherapy[J].Plast Reconstr Surg ,1997,99:1826-1830.

二级参考文献7

共引文献175

同被引文献30

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部